A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML

This study tests a new drug called clifutinib besylate combined with standard chemotherapy for people newly diagnosed with acute myeloid leukemia (AML), a fast-growing blood cancer. **You may be eligible if...** - You are 18–65 years old (Cohort 1) OR 60 or older and cannot tolerate intensive chemotherapy (Cohort 2) - You have been newly diagnosed with AML (primary or secondary to MDS) with no prior treatment - For the extended phase: your AML must have a specific genetic change called FLT3-ITD mutation - You meet the health and performance status criteria **You may NOT be eligible if...** - You have already received treatment for AML - You do not have the required genetic mutation (for extended phase) - Your overall health does not meet study requirements Talk to your doctor to see if this trial is right for you.